Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Apr 2012

Ueyama Jun-Ichi, Kure Akira, Okuno Keisuke, Sano Hitoshi, Tamoto Naohiro, Kanzaki Susumu

Abstract excerpt

Translocation (8;21)/AML1-ETO is considered a favorable cytogenetic abnormality in acute myeloid leukemia (AML). However, the outcomes associated with KIT mutations in AML1-ETO have not been elucidated. A 16-year-old boy was diagnosed with recurrent AML. Although he underwent hematopoietic stem cell transplantation (HSCT) twice, the leukemia relapsed and grew resistant to several chemotherapies. We began to treat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Imatinib Mesylate

Share to Palliative Care

Share to Piperazines

Share to RUNX1 Translocation Partner 1 Protein

Share to Thiazoles

Source

Identifiers

PMID: 22687981

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].PMID 22687981Read ↗

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.Semantic proximity Read ↗

[C-kit mutation in acute myeloid leukemia patients with AML1-ETO fusion gene and its clinical significance].Semantic proximity Read ↗

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.Semantic proximity Read ↗

AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.Semantic proximity Read ↗

AML1-ETO-positive acute myeloid leukemia presents different phenotype in pediatric and adult patientsSemantic proximity Read ↗

KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study GroupSemantic proximity Read ↗

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSemantic proximity Read ↗

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.Semantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

[Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].Semantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.Semantic proximity Read ↗

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.